Organisation paid for research Program year 2025 Source: CMS Open Payments

Precise Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$3,634,046

280 payments

Through program year 2025, Precise Clinical Research Inc is reported as receiving $3,634,046 in research payments, across 280 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$568,547	69
2024	Research	$1,148,120	91
2023	Research	$724,406	34
2022	Research	$438,885	13
2021	Research	$282,491	14
2020	Research	$253,700	21
2019	Research	$217,898	38

Breakdown

Who paid Research payments · program years 2019–2025

Teva Pharmaceuticals USA, Inc. $1,143,845 144 payments
Eli Lilly and Company $710,316 10 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $412,908 8 payments
Indivior Inc. $380,922 15 payments
AbbVie, Inc. $360,479 13 payments
Allergan Inc. $199,213 35 payments
Genentech, Inc. $163,425 25 payments
Vanda Pharmaceuticals Inc. $92,104 4 payments
Biogen, Inc. $57,668 3 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $29,291 4 payments

Studies the money was for Research payments · program years 2019–2025

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $1,086,938 65 payments
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $545,087 7 payments
An Open-Label, Multicentre Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Repeated Doses of Indv-6001 in Adults With Moderate to Severe Opioid Use Disorder $347,724 12 payments
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $207,899 2 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $163,440 2 payments
Proof of concept and DRF in BPD $157,824 3 payments
PoC in Prevention of Relapse $141,679 3 payments
A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $135,505 15 payments
Proof of concept and DRF in MDD $113,405 2 payments
Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder $92,104 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.